E. Dempsey

发表

Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children

J. Lerman, N. Sikich, D. Howard, 1996, Clinical pharmacology and therapeutics.

Usefulness of sustained-release diltiazem for stable angina pectoris.

M. Juneau, W. Kostuk, P. Pflugfelder, 1989, The American journal of cardiology.

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

J. Hainsworth, B. Zee, J. Krook, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Altering the Time of Administration and the Time Frame of Quality of life Assessments in Clinical Trials: An Example Using the EORTC QLQ-C30 in a Large Anti-Emetic Trial

D. Osoba, J. Pater, B. Zee, 1998, Quality of Life Research.

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

J. Hainsworth, J. Krook, D. Walde, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Asymptomatic Episodes of ST Segment Depression Occurring During Daily Life and During Exercise

M. Juneau, W. Kostuk, P. Pflugfelder, 2005 .

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.

Mark L. Greenberg, M. Coppes, R. Barr, 1999, Medical and pediatric oncology.

Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.

M. Coppes, C. Pratt, D. Howard, 1999, Journal of pediatric hematology/oncology.

Comparative efficacies of erythromycin-sulfisoxazole and cefaclor in acute otitis media: a double blind randomized trial.

M. Bergeron, K. Riding, J. Richard, 1987, The Pediatric infectious disease journal.

Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers.

S. Bourque, J. Spénard, E. Dempsey, 1996, Journal of clinical pharmacology.

A randomized double-blind comparison of diltiazem and nifedipine in stable angina.

W. Klinke, L. Kvill, E. Dempsey, 1988, Journal of the American College of Cardiology.

Exercise-induced myocardial ischemia in a cold environment. Effect of antianginal medications.

D. Waters, M. Juneau, M. Johnstone, 1989, Circulation.

Effect of diltiazem upon episodes of silent myocardial ischemia during daily life

D. Waters, M. Baird, M. Juneau, 1990 .

Effect of Diltiazem on Symptomatic and Asymptomatic Episodes of ST Segment Depression Occurring During Daily Life and During Exercise

D. Waters, M. Baird, M. Juneau, 1991, Circulation.

Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial.

H. Gerstein, S. Harris, J. Yale, 2008, Canadian family physician Medecin de famille canadien.

Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women.

D. Gossard, L. Roberts, M. Castles, 1997, Biopharmaceutics & drug disposition.